PIONEERING A NEW APPROACH TO THE OPIOID CRISIS
While useful in controlling pain opioids have significant limitations:
- Life-threatening respiratory and cardiovascular reactions
- Withdrawal/tolerance/addiction
- GI (motility) disruption
- Potential for mass casualties
Opioid-induced side effects have created unmet medical needs of crisis proportion, affecting millions of people annually.
THE PROBLEM: OIRD
46% of patients receiving opioids during and following surgery experience opioid-induced respiratory depression (OIRD)*:
- OIRD is a life-threatening side effect of opioids characterized by respiratory depression or cardiac collapse
- It affects millions of hospital patients every year
- OIRD extends hospital stays by 3 days on average
- Longer hospitalization increases costs by over $6,000
- Our solution addresses a $1 billion market
OIRD in hospitalized patients is Atelerix’s first target indication for opioid-related unmet medical needs.
* Source: Medtronic Prodigy Study, 2020
THE PROBLEM: WEAPONIZATION
The opioid crisis has a new and even uglier dimension – weaponization – and the focused funding interest of the NIH and the United States military.
“These public health threat agents are highly toxic chemicals that could cause mass casualties after either deliberate terrorism-related release or inadvertently.”
– National Institutes of Health
Russian special forces soldiers are seen carrying out hostages killed by a highly potent weaponized opioid in a Moscow theatre after a three-day stand off with Chechen terrorists.
(Credit: Anton Denisov/AFP/Getty Images)
THE PROBLEM: ADDICTION / TOLERENCE / OVERDOSE / WITHDRAWAL
Overdose deaths from synthetic opioids (primarily fentanyl) have become a massive crisis, approaching 40,000 in 2019, and growing since COVID-19 :
Atelerix’s novel approach to opioid-induced unmet medical needs could potentially diminish the number of opioid-related deaths
CURRENT APPROACHES FALL SHORT
The FDA-approved opioid receptor antagonists such as naloxone can reverse the most serious life-threatening opioid-induced side effects, but they:
- Also reverse the analgesic effect, leaving patients in pain
- Often elicit immediate, dangerous withdrawal behavior
- Are short-acting, requiring continuous re-administration and are only weakly effective against synthetic opioids like fentanyl
- Cannot combat opioid metabolites, which often do not work via opioid receptors
- Do nothing to modulate addiction/tolerance/withdrawal
Most ongoing research to minimize opioid-induced side effects is focused on direct targeting of opioid receptors – these efforts have largely not been successful.
THE SOLUTION: NEW APPROACH, NEW SCIENCE
A platform of novel drugs called Active Thiol-Based Compounds (ATBCs) can prevent or reverse opioid-induced side effects:
- These drugs target novel molecular pathways – modulating the signaling downstream from activated opioid receptors
- NIH-supported discovery and pre-clinical development have validated the concept, with compelling data supporting a robust pipeline of novel proprietary lead compounds
- These new drugs are now being developed for the clinic to treat opioid-induced side effects